Philips (ADR)
Builds clinical imaging, connected-care systems, respiratory equipment, and personal-health devices.
Something off on this page? Send us feedback.
Profile
Builds diagnostic imaging, image-guided therapy, patient monitoring and informatics, sleep and respiratory care, and personal-health devices. Revenue comes from Diagnosis & Treatment, Connected Care, and Personal Health, while the Respironics remediation and a federal consent decree continue to shape respiratory-device operations.
Builds diagnostic imaging, image-guided therapy, patient monitoring and informatics, sleep and respiratory care, and personal-health devices across three reportable segments: Diagnosis & Treatment, Connected Care, and Personal Health.
Combines organized research, clinical hardware, connected software, and acquired interventional and monitoring capabilities. The focused health-technology portfolio emerged through acquisitions and the separation of lighting and domestic-appliance operations.
Execution centers on product quality, patient safety, supply reliability, and business-unit accountability. Respironics ventilator remediation remains in progress, while a federal consent decree restricts covered respiratory-device manufacturing and distribution at specified US facilities until regulatory conditions are met.
Company facts
Key statistics
Year to date −1.3% · Average volume (30d) 1.1M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026Q2 FY26 | $0.41 | $0.56 | +36.6% | $4.91B | — | — | +2.15% |
| Jul 27, 2026Q2 FY26 | $0.40 | $0.57 | +42.5% | $4.91B | $4.96B | +1.1% | +2.12% |
| May 6, 2026Q1 FY26 | $0.24 | $0.27 | +12.5% | $4.49B | $4.59B | +2.2% | −0.26% |
| Feb 10, 2026Q4 FY25 | $0.57 | $0.70 | +23.9% | $5.89B | $6.07B | +3.1% | −2.55% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4.75B | $5.03B | $4.98B | $5.91B | $4.52B | $5.05B | |
| Gross profit | $2.14B | $2.33B | $2.21B | $2.65B | $2.05B | $2.49B | |
| Operating income | $178.4M | $463.5M | $382.4M | $625.7M | $279.2M | $706.8M | |
| Net income | $88.1M | $278.1M | $213.2M | $457.7M | $175.0M | $444.9M | |
| Diluted EPS | $0.09 | $0.29 | $0.22 | $0.48 | $0.19 | $0.46 | |
| Gross margin | 45.1% | 46.4% | 44.4% | 44.9% | 45.2% | 49.3% | |
| Operating margin | 3.8% | 9.2% | 7.7% | 10.6% | 6.2% | 14.0% |
Fiscal years (4-quarter sums)FY21 $19.88B · FY22 $20.66B · FY23 $21.05B · FY24 $20.88B · FY25 $20.66B
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $2.07B · Total debt $8.65B · Total assets $30.94B · Shareholders' equity $13.26B
Dividends
Last raised to $0.99 from $0.9673 in May 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| May 13, 2026 | May 13 | Jun 3 | $0.99 | raised from $0.9673 |
| May 13, 2025 | May 13 | Jun 6 | $0.9673 | raised from $0.9154 split-adjusted |
| May 9, 2024 | May 10 | May 16 | $0.9465 | cut from $0.9641 split-adjusted |
| May 12, 2022 | May 13 | Jun 8 | $0.819 |
Ownership
Shares outstanding 977.43M · Float 976.62M · 99.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Exor N.V. | 185.93M | 19.03% | 13D | Aug 21, 2026 |
| Mondrian Investment Partners Ltd | 8.07M | 0.83% | 13F | Jul 30, 2026 |
| Dimensional Fund Advisors LP | 4.34M | 0.44% | 13F | Aug 11, 2026 |
| Fiduciary Management Inc /WI/ | 3.46M | 0.35% | 13F | Aug 13, 2026 |
| Causeway Capital Management LLC | 3.06M | 0.31% | 13F | Aug 13, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- GE HealthCare
Broad overlap in imaging, ultrasound, monitoring, and hospital software
- ResMed
Direct sleep and respiratory rival in connected home care
- Medtronic
Overlaps in catheter-based therapy devices and acute-care monitoring
- Procter & Gamble
Oral-B and Braun challenge Sonicare and personal-care devices
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Philips (ADR) | $26.72 | +0.06% | $26.12B | 19.9 | 13.7 | 1.3 | −2.9% |
| GE HealthCare | $71.73 | −0.01% | $32.40B | 20.8 | 13.8 | 1.6 | +5.8% |
| ResMed | $240.33 | +0.01% | $34.86B | 23.1 | 19.8 | 6.2 | +8.6% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Procter & Gamble | $143.75 | +0.01% | $341.75B | 21.7 | 20.5 | 3.9 | +1.5% |
| Median | 22.4 | 17.6 | 3.6 | +7.2% |